ReviewPaediatric drugs2018
Rotavirus Vaccines: Effectiveness, Safety, and Future Directions.
Review in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- 15-year experience with rotavirus vaccination in Mexico: a systematic literature review.Human vaccines & immunotherapeutics · 2021Pooled it
- A phase I trial of WRSS1, aHuman vaccines & immunotherapeutics · 2019Trial
- A Global Perspective of Childhood Vaccinations: Past, Present, and Future-From Smallpox to mRNA.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Long-term Rotarix Vaccine Effectiveness in Coastal Kenya, Estimated From Child Hospital Admissions Data From July 2014 to December 2022.Open forum infectious diseases · 2026Article
- Review
- Bibliometric analysis of research progress in pediatric intussusception from the Web of Science Core Collection over the past 15 years.Medicine · 2026Article
- Prevalence and molecular epidemiology of rotavirus gastroenteritis among children in Nairobi's urban informal settlements following introduction of the Rotavac® vaccine.Tropical medicine and health · 2026Article
- Factors Associated with Rotavirus Positivity in Children with Acute Gastroenteritis in Jharkhand, India (2019-2023).Indian journal of pediatrics · 2025Article
- Article
- Multiplex Polymerase Chain Reaction Panels for Gastrointestinal Infections: Current Evidence, Regulatory Hurdles, and the Way Forward.Open forum infectious diseases · 2025Article
- Article
- Efficacy of rotavirus vaccines in Indonesia: A review of genotype distribution and impact.Narra J · 2025Review
- Article
- Interplay between nutrition, microbiota, and immunity in rotavirus infection: insights from human and animal models.Frontiers in veterinary science · 2025Review
- Trends in uptake and impact of thermostable vaccines in Africa.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Available evidence on the co-administration of the four-component meningococcal B vaccine (4CMenB) with three vaccines at the same visit among pediatric individuals.Human vaccines & immunotherapeutics · 2024Review
- Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus.Cell biochemistry and function · 2024Review
- Coverage and distributional benefit-cost of rotavirus vaccine in Uganda: an analysis of routine health facility aggregated data.Cost effectiveness and resource allocation : C/E · 2024Article
- Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Rotavirus is the leading cause of diarrheal death among children < 5 years old worldwide, estimated to have caused ~ 215,000 deaths in 2013. Prior to rotavirus vaccine implementation, > 65% of children had at least one rotavirus diarrhea illness by 5 years of age and rotavirus accounted for > 40% of all-cause diarrhea hospitalizations globally. Two live, oral rotavirus vaccines have been implemented nationally in > 100 countries since 2006 and their use has substantially reduced the burden of severe diarrheal illness in all settings. Vaccine efficacy and effectiveness estimates suggest there is a gradient in vaccine performance between low child-mortality countries (> 90%) and medium and high child-mortality countries (57-75%). Additionally, an increased risk of intussusception (~ 1-6 per 100,000 vaccinated infants) following vaccination has been documented in some countries, but this is outweighed by the large benefits of vaccination. Two additional live, oral rotavirus vaccines were recently licensed and these have improved on some programmatic limitations of earlier vaccines, such as heat stability, cost, and cold-chain footprint. Non-replicating rotavirus vaccines that are parenterally administered are in clinical testing, and these have the potential to reduce the performance differential and safety concerns associated with live oral rotavirus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.